Results 141 to 150 of about 5,297,540 (313)

Ascites circRNA ASCOR Drives Platinum Resistance of High‐Grade Serous Ovarian Cancer by Facilitating RPA1 Nuclear Translocation

Advanced Science, EarlyView.
High‐grade serous ovarian carcinoma (HGSOC) is plagued by platinum resistance, with malignant ascites closely linked to poor outcomes. Here, we identify ASCOR, a circRNA enriched in ascites small extracellular vesicles (sEVs) from platinum‐resistant HGSOC patients, as a predictor of poor survival. ASCOR enhances platinum resistance in vitro and in vivo
Hanyuan Liu, Chenchen Zhu, Xuelin Yao, Yi Liu, Jing Zhu, Yuebo Li, Hanjie Xu, Cheng Peng, Ge Shan, Liang Chen, Ying Zhou   +10 more
wiley   +1 more source

Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer.

Annals of Surgery, 2019
MINI: Total neoadjuvant therapy, or systemic induction chemotherapy followed by chemoradiation, is an optimal preoperative sequencing strategy for patients with borderline resectable or locally advanced pancreatic adenocarcinoma.
M. Truty, M. Kendrick, D. Nagorney, R. Smoot, S. Cleary, R. Graham, A. Goenka, C. Hallemeier, M. Haddock, W. Harmsen, A. Mahipal, R. McWilliams, T. Halfdanarson, A. Grothey   +13 more
semanticscholar   +1 more source

Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next‐Generation Approaches

Advanced Science, EarlyView.
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey, Sudhir Kumar Rai, Li Ma, Lauren Higa, Vedbar Khadka, Hua Yang, Youping Deng   +6 more
wiley   +1 more source

Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer

Science Translational Medicine, 2019
A robust personalized ctDNA test, TARDIS, achieves high accuracy for residual disease after completion of neoadjuvant therapy. Early detection, no time travel needed Analysis of tumor DNA shed into a patient’s circulation can provide a noninvasive means ...
B. R. McDonald, T. Contente-Cuomo, S. Sammut, Ahuva Odenheimer-Bergman, Brenda J Ernst, N. Perdigones, S. Chin, M. Farooq, Rosa Mejia, P. Cronin, K. Anderson, H. Kosiorek, D. Northfelt, A. McCullough, B. Patel, J. Weitzel, T. Slavin, C. Caldas, B. Pockaj, Muhammed Murtaza   +19 more
semanticscholar   +1 more source

NK Cell Activation by Platinum Boosts Immunotherapy in HR+/HER2− Breast Cancer

Advanced Science, EarlyView.
Multi‐omics and single‐cell analyses identify activated NK cells as key mediators of anti‐PD‐(L)1 response in HR+/HER2− breast cancer. Platinum chemotherapy enhances NK cell cytotoxicity through NF‐κB–associated signaling, synergizing with immunotherapy and providing a rationale for combination treatment.
Yi‐Yu Chen, Yi‐Fan Zhou, Xuan Qi, Ya‐Xin Zhao, Tong Fu, Xi Jin, Minhong Shen, Yi‐Zhou Jiang, Zhi‐Ming Shao   +8 more
wiley   +1 more source

NIPAL1 Drives a Metabolic‐Epigenetic Feedback Loop to Promote Lactate‐Mediated Immune Evasion in Esophageal Cancer

Advanced Science, EarlyView.
The study identifies a NIPAL1‐driven metabolic‐epigenetic circuit in esophageal squamous cell carcinoma that promotes glycolysis, lactate accumulation, and H3K18 histone lactylation, forming a self‐sustaining loop that suppresses CD8+ T cell immunity.
Ri‐Xin Chen, Xiao‐Dan Ma, Shui‐Dan Xu, Ao‐Tian Mo, Min‐Hua Deng, Jun‐Han Wu, Wei‐Tao Zhuang, Jin‐Ling Duan, Shu‐Huan Xie, Jin‐Long Lin, Peng Lin, Ji‐Ming Tang, Hai‐Yu Zhou, Xiao‐Song Ben, Gui‐Bin Qiao, Dan Xie   +15 more
wiley   +1 more source

Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer

Nature Medicine, 2022
W. Chatila, Jin K. Kim, H. Walch, Michael R. Marco, Ching-Tung Chen, Fan Wu, D. Omer, D. Khalil, K. Ganesh, X. Qu, A. Luthra, Seo-Hyun Choi, Yu-jui Ho, R. Kundra, Katharine I Groves, O. Chow, A. Cercek, M. Weiser, M. Widmar, I. Wei, E. Pappou, G. Nash, P. Paty, Q. Shi, E. Vakiani, S. Duygu Selcuklu, M. Donoghue, D. Solit, M. Berger, J. Shia, Raphael A. Pelossof, P. Romesser, R. Yaeger, J. Smith, N. Schultz, F. Sánchez-Vega, J. García-Aguilar   +36 more
semanticscholar   +1 more source

T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities

Advanced Science, EarlyView.
T cell exhaustion limits immunotherapy efficacy. This article delineates its progression from stem‐like to terminally exhausted states, governed by persistent antigen, transcription factors, epigenetics, and metabolism. It maps the exhaustion landscape in the TME and proposes integrated reversal strategies, providing a translational roadmap to overcome
Yang Yu, Xiaoyu Yao, Qingyang Wang, Mengrui Yang, Runze Li, Jiangjiang Qin, Jing Zhuang, Changgang Sun   +7 more
wiley   +1 more source

The ITGB2‐COPS3‐SOX2 Axis and SOX2 Liquid‐Liquid Phase Separation: Dual Mechanisms Governing Osteosarcoma Stemness

Advanced Science, EarlyView.
Osteosarcoma stemness is driven by the ITGB2‐COPS3‐SOX2 signaling axis. This study reveals that nuclear COPS3 stabilizes SOX2, which in turn undergoes liquid‐liquid phase separation to promote stemness. Based on this mechanism, a novel COPS3 inhibitor, Z‐5891, was developed, effectively suppressing tumor growth and stemness in vivo, offering a ...
Lei Guo, Zhiqing Zhao, Wei Wang, Jianfang Niu, Bing Wang, Yunfei Lin, Wei Guo, Taiqiang Yan   +7 more
wiley   +1 more source

Immune Checkpoint Inhibitors and Immunomodulators for Cancer Immunotherapy: Insights Into Resistance and Therapeutic Strategies

Advanced Science, EarlyView.
The schematic diagram illustrates the roles of novel immune checkpoints, immunomodulatory factors, cell death and multimodal technologies in cancer immunotherapy. Abstract Cancer immunotherapy has redefined cancer treatment. However, the molecular and cellular basis of immune evasion and therapeutic resistance remains incompletely understood.
Fangquan Chen, Yang Yu, Xiutao Cai, Junhao Lin, Ruirui Liang, Rui Kang, Daolin Tang, Jiao Liu   +7 more
wiley   +1 more source